Balentine LLC’s Nektar Therapeutics NKTR Stock Holding History

Balentine LLC’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10	Closed	-$4K	–	617
2020 Q2	$4K	Hold	10	–	–	﹤0.01%	773
2020 Q1	$3K	Hold	10	–	–	﹤0.01%	545
2019 Q4	$3K	Buy	+10	New	+$2.9K	﹤0.01%	508

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Balentine LLC's NKTR Position: Q3 2020 in Review

Balentine LLC sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 10 shares — an estimated $4K sold.

Balentine LLC first reported a position in NKTR in Q4 2019 and held it in 3 quarters. The position peaked at $4K in Q2 2020. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

Balentine LLC reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
Balentine LLC sold 10 Nektar Therapeutics shares in Q3 2020, an estimated $4K.
Balentine LLC first reported a position in Nektar Therapeutics in Q4 2019 and held it in 3 quarters.
Balentine LLC's Nektar Therapeutics position peaked at $4K in Q2 2020.
249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.